Physician profile
Samir Vira
NPI 1679725550
$2,490.68
in general payments reported to CMS, 2019-2025
21 companies · $200 in 2025
The $200 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2020: $186 · 2021: $378 · 2022: $505 · 2023: $770 · 2024: $269 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,222 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,221.70 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $534.72 | 2019-2025 | Tecnis Iol, Tecnis Iol, Amo Phaco Needle |
| Alcon Vision LLC | $326.32 | 2020-2025 | Hydrus Microstent, Luxor, Argos |
| Rxsight INC | $295.48 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Sight Sciences, INC. | $234.23 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Glaukos Corporation | $158.82 | 2019-2023 | Kxl System (Not Refurbished) |
| Oyster Point Pharma, INC. | $118.59 | 2022-2025 | Tyrvaya |
| Biotissue Holdings INC. | $110.43 | 2019-2024 | |
| Dompe US, INC. | $100.10 | 2019-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $87.60 | 2023 | Miebo, Vyzulta |
| Harrow Eye, LLC | $85.37 | 2024 | Vevye |
| Sun Pharmaceutical Industries INC. | $71.19 | 2022 | |
| Ivantis, INC | $68.41 | 2020-2021 | |
| Allergan, INC. | $67.19 | 2020-2022 | |
| Carl Zeiss Meditec, INC. | $36.11 | 2023 | |
| Carl Zeiss Meditec Ag | $34.40 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $33.12 | 2024 | |
| Horizon Therapeutics Plc | $28.79 | 2023 | Tepezza |
| Eyepoint US, INC. | $28.30 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $27.12 | 2021 | |
| Mallinckrodt Hospital Products INC. | $24.50 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Vira listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.